These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32416364)

  • 1. Anticoagulation control in different ethnic groups receiving vitamin K antagonist therapy for stroke prevention in atrial fibrillation.
    Zulkifly H; Cheli P; Lutchman I; Bai Y; Lip GYH; Lane DA
    Thromb Res; 2020 Aug; 192():12-20. PubMed ID: 32416364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention.
    Zulkifly H; Lip GYH; Lane DA
    Int J Clin Pract; 2022; 2022():5951262. PubMed ID: 35685589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
    Vinding NE; Bonde AN; Rørth R; Lamberts M; Olesen JB; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL
    Europace; 2019 Apr; 21(4):572-580. PubMed ID: 30508073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation.
    Chan PH; Li WH; Hai JJ; Chan EW; Wong IC; Tse HF; Lip GY; Siu CW
    Can J Cardiol; 2016 Oct; 32(10):1247.e23-1247.e28. PubMed ID: 26927855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland.
    Maeder MT; König T; Bogdanovic S; Schneider I; Eugster W; Ammann P; König M; Beer J; Rickli H
    Swiss Med Wkly; 2017; 147():w14503. PubMed ID: 29039622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving Vitamin K Antagonists.
    Zulkifly HH; Pastori D; Lane DA; Lip GYH
    J Clin Med; 2023 Feb; 12(3):. PubMed ID: 36769789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.
    Mearns ES; White CM; Kohn CG; Hawthorne J; Song JS; Meng J; Schein JR; Raut MK; Coleman CI
    Thromb J; 2014; 12():14. PubMed ID: 25024644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
    Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
    Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of INR control and switching to non-Vitamin K oral anticoagulants between women and men with atrial fibrillation treated with Vitamin K Antagonists in Spain. A population-based, real-world study.
    García-Sempere A; Hurtado I; Bejarano-Quisoboni D; Rodríguez-Bernal C; Santa-Ana Y; Peiró S; Sanfélix-Gimeno G
    PLoS One; 2019; 14(2):e0211681. PubMed ID: 30753227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
    Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.
    Haas S; Ten Cate H; Accetta G; Angchaisuksiri P; Bassand JP; Camm AJ; Corbalan R; Darius H; Fitzmaurice DA; Goldhaber SZ; Goto S; Jacobson B; Kayani G; Mantovani LG; Misselwitz F; Pieper K; Schellong SM; Stepinska J; Turpie AG; van Eickels M; Kakkar AK;
    PLoS One; 2016; 11(10):e0164076. PubMed ID: 27792741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulation control among patients on vitamin K antagonists in nine countries in Sub-Saharan Africa.
    Mwita JC; Francis JM; Pillay C; Ogah OS; Goshu DY; Agyekum F; Musonda JM; James MC; Tefera E; Kabo T; Ditlhabolo KI; Ndlovu K; Ayodele AY; Mikomangwa WP; Chillo P; Damasceno A; Folson AA; Oyekunle A; Tebuka E; Kalokola F; Forrest K; Dunn H; Karaye K; Jean-Pierre FL; Oljira CF; Assefa T; Taiwo TS; Nwafor CE; Omole O; Anakwue R; Cohen K
    J Thromb Thrombolysis; 2024 Apr; 57(4):613-621. PubMed ID: 38478250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the mean time in the therapeutic INR range and the SAME-TT2R2 score in patients with atrial fibrillation and cognitive impairment.
    Gorzelak-Pabiś P; Zyzak S; Krewko Ł; Broncel M
    Pol Arch Med Wewn; 2016 Aug; 126(7-8):494-501. PubMed ID: 27511466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists.
    Abumuaileq RR; Abu-Assi E; Raposeiras-Roubin S; López-López A; Redondo-Diéguez A; Álvarez-Iglesias D; Rodríguez-Mañero M; Peña-Gil C; González-Juanatey JR
    Europace; 2015 May; 17(5):711-7. PubMed ID: 25662984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of Warfarin Anticoagulation in Indigenous and Non-Indigenous Australians With Atrial Fibrillation.
    Nguyen MT; Gallagher C; Pitman BM; Emami M; Kadhim K; Hendriks JM; Middeldorp ME; Roberts-Thomson KC; Mahajan R; Lau DH; Sanders P; Wong CX
    Heart Lung Circ; 2020 Aug; 29(8):1122-1128. PubMed ID: 31980393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score.
    Apostolakis S; Sullivan RM; Olshansky B; Lip GYH
    Chest; 2013 Nov; 144(5):1555-1563. PubMed ID: 23669885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry.
    Esteve-Pastor MA; Rivera-Caravaca JM; Roldán-Rabadán I; Roldán V; Muñiz J; Raña-Míguez P; Ruiz-Ortiz M; Cequier Á; Bertomeu-Martínez V; Badimón L; Anguita M; Lip GYH; Marín F;
    Europace; 2018 Sep; 20(9):1435-1441. PubMed ID: 29095971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national and multicentre SULTAN registry.
    Rivera-Caravaca JM; Badimón L; Ferreira-Gonzalez I; Gómez-Doblas JJ; Roca-Luque I; Lekuona I; Jiménez-Candil J; Rodríguez-Padial L; González-Juanatey C; Calvo-Jambrina R; Fácila L; Ruiz-Ortiz M; Anguita M; Marín F
    Europace; 2022 Jan; 24(1):4-11. PubMed ID: 34115857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and management of patients with stroke and major hemorrhagic episodes with atrial fibrillation under vitamin K antagonist therapy. EVENTHO study.
    Gavín O; Roldán V; Llamas-Sillero P; Santamaría A; Arumí D; Cabo SF
    Med Clin (Barc); 2022 Oct; 159(8):366-371. PubMed ID: 35120766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality control of oral anticoagulation with vitamin K antagonists in primary care patients in Poland: a multi-centre study.
    Sawicka-Powierza J; Buczkowski K; Chlabicz S; Gugnowski Z; Powierza K; Ołtarzewska AM
    Kardiol Pol; 2018; 76(4):764-769. PubMed ID: 29313558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.